b'USMAd_v1.pdf 1 11/30/21 7:55 AMAVAILABLE ON THE VA NATIONAL FORMULARY AND TRICARE PROTECTING OUR VETERANS AND ACTIVE MILITARY FROM HEPATITIS BIS AS EASY AS 12 DOSES. 1 MONTH. DONE.HEPLISAV-B IS UNANIMOUSLY RECOMMENDED BY THE ACIP 2HEPLISAV-B is the only 2-dose, 1-month hepatitis B vaccine for adults1,3Series completion is essential to protectionbut ~75% of adults do not complete a 3-dose, 6-month hepatitis B vaccine series 4,5In a large real-world study GREATER SERIES COMPLETION AND FAST, 6 EFFICIENT PROTECTION 1,6Higher rates of protection than Engerix-B even in adults with health factors common in the VA population 1,7-11TRIAL 3: Percentage of People Aged 18 to 70 Achieving Protective Immunity 1,7 *PATIENTS WITH DIABETES TOTAL TRIAL POPULATION MALE AGED 40 TO 70 OBESITY SMOKERSN=961 N=6665 N=3353 N=5434 N=3241 N=2082HEPLISAV-B Engerix-B HEPLISAV-B 95.4 % 94.5 % 94.6 % 94.7 % 95.9 %90.0 % VS65.1 % VSVSVSVSVS Engerix-B 81.3 % 78.8 % 78.7 % 75.4 % 78.6 %* Protective immunity de ned as antibody concentration 10 mIU/mL.12A SAFETY PROFILE SIMILAR TO ENGERIX-B WAS DEMONSTRATED IN MORE THAN 10,000 ADULTS 13Abbreviations: ACIP, Advisory Committee on Immunization Practices; VA, Veterans A airs.INDICATIONHEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.IMPORTANT SAFETY INFORMATIONDo not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).heplisavb.comPlease see Brief Summary of full Prescribing Information on the following pages.REFERENCES: 1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 2. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67(15):455-458. 3. Freedman M, Kroger A, Hunter P, Ault KA. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med. 2020;172(5):337-347. 4. Williams WW, Lu PJ, OHalloran A, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017;66(11):1-28. 5. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33. 6. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. 2020;3(11):e2027577. doi:10.1001/jamanetworkopen.2020.27577. 7. Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018;36(5):668-674. 8. Lui Y, Sayam S, Shao X, et al. Prevalence of and trends in diabetes among veterans, United States, 20052014. Prev Chronic Dis. 2017;14:E135. 9. Centers for Disease Control and Prevention. About three in ten US veterans use tobacco products. https://www.cdc.gov/media/releases/2018/p0111-tobacco-use-veterans.html. Published January 11, 2018. Accessed August 19, 2021. 10. Breland JY, Phibbs CS, Hoggatt KJ, et al. The obesity epidemic in the Veterans Health Administration: prevalence among key populations of women and men veterans. J Gen Intern Med. 2017;32(suppl 1):11-17. doi:10.1007/s11606-016-3962-1. 11.US Department of Veterans A airs. Table 1L: VETPOP2018 living veterans by age group, gender, 2018-2048. https://www.va.gov/vetdata/veteran_population.asp. Accessed August 19, 2021.12. Centers for Disease Control and Prevention. Hepatitis B. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington, DC: Public Health Foundation; 2015:149-174. https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf. Accessed August 18, 2021. 13. Dynavax Technologies Corporation. FDA Advisory Committee Brie ng Document: HEPLISAV-B (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD. 2021 Dynavax Technologies Corporation. All rights reserved. August 2021 US-21-00-00202 2 DOSES. 1 MONTH. DONE. 1'